New hope for lung cancer patients too weak for standard chemo?
NCT ID NCT04297605
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with advanced non-small cell lung cancer who are not well enough for standard strong chemotherapy. It tests a combination of one chemotherapy drug and an immunotherapy drug (pembrolizumab) to see if it is safe and helps shrink tumors. About 60 participants will take part, and the goal is to find a treatment option that is both tolerable and effective for this group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Rochester
NOT_YET_RECRUITINGRochester, New York, 14642, United States
-
University of Rochester
RECRUITINGRochester, New York, 14642, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?